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Paediatric therapy related acute myeloid leukaemia (t-AML) is rare and the outcome is poor. While 
allogeneic haematopoietic stem cell transplantation (HSCT) is generally the accepted modality of 
treatment, data regarding salvage chemotherapy, remission induction, conditioning regimens, 
transplant related mortality and outcome is scarce. Between 2000-2016, 36 children with t-AML 
were treated in seven UK paediatric HSCT centres. The most common salvage protocol for remission 
induction was FLAG with or without idarubicin and 28 patients were in complete morphological 
remission prior to BMT. Only 12 patients survived (33%). Transplant related mortality (TRM) was the 
leading cause of death.  
INTRODUCTION 
Therapy related acute myeloid leukaemia (t-AML) is a well-recognized clinical subtype of AML.  [1] t-
AML occurring in adults is usually associated with inferior outcome compare with de novo AML. [2-4] 
Although more children now survive their first cancer, data on paediatric outcomes of t-AML is 
limited, outcome historically has been very poor (15-30%) and generally allogeneic HSCT is the 
treatment modality of choice. [5-7] Furthermore, it is not known whether the inferior outcome is 
due to disease relapse or transplant related mortality. Our aim herein was to retrospectively assess 
the outcome of children who were diagnosed with t-AML and received HSCT in a dedicated JACIE 
accredited paediatric UK transplant centre. 
PATIENTS AND METHODS 
A survey questionnaire was sent to all UK Paediatric HSCT centres asking centres to identify children 
(0-18 years) who were transplanted in their centres for a diagnosis of t-AML from January 2000 – 
January 2016. Definition of t-AML was according to the WHO criteria. [1] Electronic data collection 






SAS software was used to carry out the statistical analyses. Time to event (relapse or death) and the 
probability of event free survival (EFS) and overall survival (OS) for different endpoints was 
determined using Kaplan–Meier curves. The association between pairs of categorical variables was 
evaluated using Fisher’s exact test.  A two tailed p value of <0.05 was considered to be statistically 
significant. The cumulative incidence of relapse and treatment-related mortality was estimated 
taking into account the competing risks of other events. Given the small number of survivors, a Cox 
proportional hazard survival model was not possible and the impact of different variables on survival 
was descriptive. Transplant related mortality (TRM) was defined as any death in remission. 
RESULTS 
Seven UK paediatric HSCT centres participated in the study and sent data regarding children who 
received HSCT for t-AML. Total number of patients was 37, however, one child with t-AML and a 
previous diagnosis of neuroblastoma died within 2 days of the diagnosis of t-AML and did not 
receive HSCT and was therefore excluded from the study. Median time from the original diagnosis to 
the diagnosis of t-AML was 3.8 years (1-9.5 years).   
Cytogenetics results were available in 30 patients and 23 of them had poor risk cytogenetics (p=0.02) 
including MLL rearrangements, monosomy 7 and complex karyotype (see Table 1). Fourteen patients 
had received radiotherapy as part of their treatment for first cancer. Fludarabine, high dose 
cytarabine, and granulocyte colony stimulating factor (FLAG) with or without idarubicin (FLAG-Ida) 
was the most common salvage regimen prior to HSCT. Remission status prior to HSCT was known in 
28 patients, 24 were in complete remission (CR) prior to HSCT leading to a statistically significant 
likelihood to enter remission prior to HSCT (p=0.001). The majority (28 patients) received a graft 
from an unrelated donor (18 from an unrelated adult donor and 10 from a cord unrelated progenitor 
stem cell source). Conditioning regimens varied among centres – overall 28 patients received 
myeloablative regimens (TBI based in 8 patients) and 6 patients received reduced intensity 
conditioning. All patients received cyclosporine A (CSA) as GVHD prophylaxis. Recipients of unrelated 
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donor graft received campath 1H as serotherapy and recipients of cord progenitor stem cells 
received mycophenolate mofetil (MMF) along with CSA. A further agent for GVHD prophylaxis such 
as methotrexate or MMF was added to the CSA for mismatched unrelated grafts. Table 1 
summarises patient and transplant characteristics.  
SURVIVAL 
One patient was lost to follow up, therefore, survival outcome was available on 35 patients. At a 
median follow up of 7.3 years (range 2.1 - 16.1) 12 patients are long term survivors (OS = 34%) and 
23 patients have died. Thirteen out of the 23 patients (56%) died from TRM and 10 patients (44%) 
died from disease relapse giving an overall TRM rate of 37% and a relapse rate of 29%. All patients 
who relapsed died, therefore EFS and OS was the same (figure 1). Potential variables that had an 
impact on survival were as follows: 1. t-AML secondary to solid tumour vs t-AML secondary to 
haematological/lymphoid malignancy. 2. Donor source (living unrelated donor vs unrelated cord vs 
matched sibling donor). 3. Poor risk cytogenetics. 4. Conditioning regimens. 
There were 17 patients with t-AML post a solid tumour and 11 of them died post HSCT and 12 out of 
the 18 patients with t-AML post haematological/lymphoid malignancy have died post HSCT. Eighteen 
patients received HSCT from a living UD and 11 died (TRM=5, relapse=6). Ten patients received 
unrelated cord progenitor stem cells and 8 died post HSCT (TRM=6, relapse=2). Eight patients 
received matched sibling donor and 4 died (TRM=2, relapse=2). Twenty-three patients had poor risk 
cytogenetics. Five out of nine patients with MLL gene rearrangement died, 3 from TRM and 2 from 
relapsed disease. Five out of nine patients with monosomy 7 died, 4 from TRM and 1 from relapsed 
disease. All patients with complex cytogenetics (n=5) died, 3 from TRM and 2 from relapsed disease. 
Therefore, 8 out of 23 patients with poor risk cytogenetics are alive compared to 4 out of 12 patients 
without poor risk cytogenetics (P = NS). As for the conditioning regimens; of 9 patients who were 
conditioned with fludarabine, treosulphan and thiotepa (FTT) or fludarabine and treosulphan (FT), 7 
have died, 4 from TRM and 3 from relapsed disease. Of those who were conditioned with 
BU/CY/Mel (n=8), 5 have died, 4 from TRM and 1 from relapsed disease. Eight patients were 
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conditioned with CY/TBI and 4 have died, 2 from TRM and 2 from relapsed disease and 6 patients 
were conditioned with FLU/Mel and 4 have died 1 from TRM and 3 from relapsed disease. Those 
who did not achieve remission prior to BMT (n=4) 3 of them died post BMT, 2 from TRM and 1 from 
relapsed disease. Seventeen patients had acute GVHD, grade I in 4 patients (1 died from TRM), grade 
II in 6 patients (2 died from relapse and 2 died from TRM), grade III in 2 patients and both died from 
TRM and grade IV in 5 patients (2 died from TRM and 1 died from relapse). Therefore, 7 patients 
with GVHD died from TRM, 5 from multi organ failure and 2 from sepsis. The cause of TRM in the 
remaining 6 patients who did not have GVHD were as follows; pneumonitis with respiratory failure 
(n=3), adeno virus infection (n=1), pseudomans aeruginosa sepsis (n=1) and multi organ failure 
(n=1). 
DISCUSSION 
In this multi-centre retrospective paediatric study for t-AML and HSCT, we found that the majority of 
t-AML is associated with poor risk cytogenetics. However, remission induction and maintaining 
remission to proceed to HSCT was possible in the majority of patients. Furthermore, the main cause 
of death was TRM rather than relapse and a survival of 34% was similar to other published reports of 
t-AML. [3-8] 
Among 2589 children with cancer treated at MD Anderson, Aguilera et al reported 22 children with 
t-AML who were treated differently with some subtle differences in their outcome. Three patients 
received supportive care only. Group 1 (n=5) underwent HSCT without induction chemotherapy. 
Group 2 (n=5) patients received AML-type chemotherapy and HSCT post remission (n=5). Group 3 
(n=4) received HSCT as salvage therapy. The respective 2-year survival rates for groups 1, 2, and 3 
were 20%, 40%, and 25% (P=0.85). [9] Due to the small number of patients there was no statistical 
significance difference in their outcome. However, group 2 which included patients who received 
AML-type chemotherapy followed by HSCT had the best outcome. In our study all patients with t-
AML were treated following the same principle since post HSCT outcome is generally superior if 
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patients achieve good remission prior to HSCT and achieving remission prior to HSCT was possible in 
the majority of our patients. 
t-AML is recognized as an independent poor prognostic factor among AML. [10] Nonetheless, in our 
study, the main cause of death was TRM rather than disease relapse. We acknowledge the fact that 
TRM is a competing risk for disease relapse and it is unknown how many of the patients who died 
from TRM would have relapsed if they lived longer. Woodard et al analysed the results of allogeneic 
HSCT in 38 children with t-AML to determine which factors, if any, affected outcome. Three-year OS 
and EFS were the same (15.4 +/- 5.8%) and a very high 3-year TRM (59.6 +/- 8.4%). [11] This high 
TRM incidence was similarly observed in our study. A large adult study analysed outcomes in 868 
persons with t-AML (n=545) or t-MDS (n=323) receiving allogeneic transplants from 1990 to 2004. 
EFS and OS were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 
5 years, respectively. In a In multivariate analysis, 4 risk factors had adverse impacts on EFS and OS: 
(1) age older than 35 years; (2) poor risk cytogenetics; (3) t- AML not in remission or advanced t-
MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated 
donor. [12] In our paediatric study survival statistical model was not possible due to small number of 
patients. 
While it is not possible to change the t-AML aggressive disease biology and high risk features, there 
may be some measures that could be taken to reduce TRM. We believe that this high TRM incidence 
was caused by the heavily pre-treated status of these patients since all patients received multiple 
cycles of chemotherapy for their original cancer and strong salvage chemotherapy for the t-AML, 
FLAG or FLAG/Ida. Furthermore, almost all patients received 2 cycles of FLAG prior to HSCT but the 
majority were in remission after the first cycle. Therefore, provided a suitable donor is available and 
the patient is in remission, proceeding to HSCT after one cycle of FLAG/Ida may lead to a reduction 
in TRM. 
Another factor that may have contributed to the high incidence of TRM was the choice of the 
conditioning regimen. Our observation suggests the children who received a fully myeloablative 
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conditioning regimen such as BU/CY/Mel have a high TRM rate (50%), while those who received a 
reduced intensity conditioning regimen such as FLU/Mel had a high relapse rate (50%). It is possible 
that a reduced toxicity rather than a reduced intensity regimen such as BU/FLU may lead to a 
reduction of TRM while preserving anti leukaemic activity. [13-15]. Within the UK, we plan to 
investigate this approach prospectively. 
We acknowledge the limitation of our study, in particular, the retrospective design and that survival 
model statistical analysis was not possible due to the limited number of patients. However, our 
observations suggests that TRM is the main cause of death in this very high risk paediatric 
malignancy and potential measures such as reduction of salvage chemotherapy after achieving 
remission and a careful choice of the conditioning regimen may be helpful in reducing TRM. Larger 
prospective studies are required. 
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